Kangstem Biotech Co., Ltd.
- Biotech or pharma, therapeutic R&D
Kangstem Biotech is a Korean company developing innovative therapies using UCB-MSCs (INN: Osirarmestrocel).
Our lead program, OSCA, combines Osirarmestrocel with CAM in a single intra-articular injection, which has shown significant reductions in pain and inflammation, as well as structural cartilage improvement confirmed by MRI at 6 &12M in both non-clinical studies and a P1 PoC trial.
Secondly, we conducted P1 through P3 trials with a single subcutaneous injection of Osirarmestrocel for the treatment of atopic dermatitis. Currently, based on the results of a repeated-dose P1 trial, we are conducting a repeated-dose P2 trial.
Lastly, leveraging our skin organoid platform, we have developed disease-induced skin organoids and established an evaluation system to compare the efficacy of approved drugs and investigational candidates. We are currently engaged in licensing discussions with several multinational pharmaceutical companies based on the strength of this platform.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}